Annandale Capital’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.04M | Hold |
75,552
| – | – | 0.08% | 66 |
|
|
2025
Q1 | $836K | Hold |
75,552
| – | – | 0.05% | 71 |
|
|
2024
Q4 | $805K | Hold |
75,552
| – | – | 0.13% | 71 |
|
|
2024
Q3 | $960K | Hold |
75,552
| – | – | 0.13% | 70 |
|
|
2024
Q2 | $1.27M | Sell |
75,552
-6,000
| -7% | -$101K | 0.22% | 66 |
|
|
2024
Q1 | $1.22M | Sell |
81,552
-279
| -0.3% | -$4.18K | 0.23% | 64 |
|
|
2023
Q4 | $1.23M | Hold |
81,831
| – | – | 0.23% | 67 |
|
|
2023
Q3 | $1.15M | Sell |
81,831
-2,500
| -3% | -$35K | 0.29% | 56 |
|
|
2023
Q2 | $873K | Hold |
84,331
| – | – | 0.25% | 68 |
|
|
2023
Q1 | $779K | Hold |
84,331
| – | – | 0.25% | 65 |
|
|
2022
Q4 | $748K | Hold |
84,331
| – | – | 0.25% | 67 |
|
|
2022
Q3 | $702K | Hold |
84,331
| – | – | 0.26% | 70 |
|
|
2022
Q2 | $691K | Hold |
84,331
| – | – | 0.27% | 65 |
|
|
2022
Q1 | $735K | Sell |
84,331
-1,923
| -2% | -$16.8K | 0.29% | 63 |
|
|
2021
Q4 | $820K | Hold |
86,254
| – | – | 0.36% | 61 |
|
|
2021
Q3 | $1.45M | Hold |
86,254
| – | – | 0.87% | 28 |
|
|
2021
Q2 | $1.32M | Hold |
86,254
| – | – | 0.79% | 31 |
|
|
2021
Q1 | $1.68M | Hold |
86,254
| – | – | 1.19% | 23 |
|
|
2020
Q4 | $1.55M | Buy |
+86,254
| New | +$1.55M | 1.3% | 22 |
|